Phase 2 Chronic Rhinosinusitis Trial, Not Yet Recruiting (NCT07519577)

Phase 2 Chronic Rhinosinusitis Trial, Not Yet Recruiting NCT07519577 Sponsor: Keymed Biosciences Co.Ltd Condition: Chronic Rhinosinusitis

Printed from Voxsanity (voxsanity.com.au) — NCT07519577 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Chronic Rhinosinusitis

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You previously took part in a specific clinical study of a drug called CM512 for chronic sinusitis with nasal polyps (the study numbered CM512-102101).

Who may not be able to join:

You have not waited long enough since your last treatment — for example, less than 10 weeks (or 5 half-lives, whichever is longer) since taking a certain type of allergy/immune-blocking medication, less than 8 weeks since a biological or immune-suppressing therapy, or less than 6 months since sinus surgery (including polyp removal) (confirm with trial site).
You have a tumour (cancerous or non-cancerous) in your nasal cavity.
You received a live vaccine (a type of vaccine made with a weakened live virus or bacteria) within the 30 days before the start of the study, or you are planning to receive one during the study.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 028-88610620

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07519577

Sponsor: Keymed Biosciences Co.Ltd

Phase: Phase 2

Status: Not Yet Recruiting

Condition: Chronic Rhinosinusitis

Trial contact: 028-88610620

More information: https://clinicaltrials.gov/study/NCT07519577

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You previously took part in a specific clinical study of a drug called CM512 for chronic sinusitis with nasal polyps (the study numbered CM512-102101).

Who may not be able to join:

You have not waited long enough since your last treatment — for example, less than 10 weeks (or 5 half-lives, whichever is longer) since taking a certain type of allergy/immune-blocking medication, less than 8 weeks since a biological or immune-suppressing therapy, or less than 6 months since sinus surgery (including polyp removal) (confirm with trial site).
You have a tumour (cancerous or non-cancerous) in your nasal cavity.
You received a live vaccine (a type of vaccine made with a weakened live virus or bacteria) within the 30 days before the start of the study, or you are planning to receive one during the study.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Not Yet Recruiting

Phase

Phase 2

Sponsor

Keymed Biosciences Co.Ltd

Registry

ClinicalTrials.gov

Start date

31 May 2026

Est. completion

31 May 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Occurrence of adverse events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov